Search clinical trials for: DPP4 inhibitor (Linagliptin 5 MG)

Total 8136 results

Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
Boehringer Ingelheim
Eli Lilly and Company

Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

United States, Estonia, Germany, Latvia, Spain, United Kingdom
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
SINA Health Education and Welfare Trust
Horizon Pharmaceutical Pvt Ltd

Completed

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Hypoglycemic Agents | Empagliflozin

Pakistan
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
The University of Texas Medical Branch, Galveston

Terminated

Fatty Liver Study in Patients With Type II Diabetes

Type II Diabetes | Nonalcoholic Fatty Liver

United States
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
University of British Columbia
Merck Frosst Canada Ltd.

Completed

Sitagliptin in the Elderly

Type 2 Diabetes

Canada
Oslo University Hospital
Vestre Viken Hospital Trust; University of Oslo; The Research Council of Norway; University Hospital, Akershus and other collaborators

Recruiting

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (DIASA3)

Glucose Metabolism Disorders | Impaired Glucose Tolerance | Insulin Sensitivity

Norway
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
The Catholic University of Korea

Completed

DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Mayo Clinic

Recruiting

Anti-Diabetic Medications to Fight PD and LBD

Parkinson Disease | Lewy Body Dementia

United States
Amsterdam UMC, location VUmc

Completed

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS)

Type 2 Diabetes

Netherlands
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (SUSTAIN)

Diabetes Mellitus, Type 2 | Diabetes

Taiwan, Korea, Republic of, South Africa, Hong Kong, Brazil, China, Ukraine
JW Pharmaceutical

Completed

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (ACACIA)

Type 2 Diabetes

Korea, Republic of
University of Dundee

Completed

Study of Sulphonylurea Synergy With DPP4 Inhibitors (SSS)

Type 2 Diabetes

United Kingdom
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
Shanghai 10th People's Hospital

Completed

Non-alcoholic Fatty Liver Disease and Its Treatment

NAFLD
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
University of British Columbia

Terminated

Sitagliptin in Cystic Fibrosis-Related Diabetes

Cystic Fibrosis

Canada
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
University of British Columbia
Merck Sharp & Dohme LLC

Terminated

Effect of Sitagliptin on Graft Function Following Islet Transplantation

Islet Transplantation

Canada
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Healthcare Pharmaceuticals

Recruiting

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Spondyloarthritis, Axial

Bangladesh
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Type 2 Diabetes

China
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Diabetes Mellitus, Type 2

United States

3

Subscribe